전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved179 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleMiltenyi Biotec, Inc.Phase 1

Autologous CAR19 T lymphocytes (Autologous CAR19 T lymphocytes)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 7Status Recruiting
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD22

#CD22#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 6Status Recruiting
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

C-CAR-011 (C-CAR-011)

Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 6Status Discontinued
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART22 cells (CART22 cells)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Discontinued
CGTLimited DatastaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (CD19-CAR-DNT cells)

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy (Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Discontinued
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#monoclonal-antibody#Hoffmann-La
Trials 4Status Active
ADCLimited DatastaleSeagen Inc.Phase 2

denintuzumab mafodotin (denintuzumab mafodotin)

Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-cell

#LymphomaB-cell#ADC#Phase2#antibody-drug-conjugate#Lymphoma+2
Trials 4Status Discontinued
CGTLimited DatastaleXinqiao Hospital of ChongqingPhase 1

in vivo CAR-T drug based on LNP-mRNA (in vivo CAR-T drug based on LNP-mRNA)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 4Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 2

Bispecific antibody-based combined with CAR-T cell therapy (Bispecific antibody-based combined with CAR-T cell therapy)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#monoclonal-antibody#Genentech
Trials 3Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

1.0 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^6 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

7.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleKecellitics Biotech Company LtdPhase 2

CD19 and CD22 targeted CAR-T cells (CD19 and CD22 targeted CAR-T cells)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleInnovative Cellular Therapeutic…Preclinical

CD19CART (CD19CART)

Leukemia, B-Cell; Lymphoma, B-Cell · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 3Status Active
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-CD19 UCAR-NK cells (Anti-CD19 UCAR-NK cells)

B-cell Lymphoma; B-cell Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Discontinued
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 1

Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes)

Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent B-Cell Non-Hodgkin Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Discontinued
CGTLimited DatastaleNeoImmuneTechPhase 1

CAR T-cell therapy (CAR T-cell therapy)

Large B-cell Lymphoma · Large B-cell Lymphoma

#LargeB-cellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 2Status Active

3 / 9 pages

← PreviousNext →